Expanding the sample size and performing additional immunohistochemistry across various PTC stages confirmed that MERTK expression in tumor cells aligns with trends observed in single‐cell data, suggesting that MERTK protein could serve as a biomarker for early diagnosis of PTMC progression. The gene discussed is MERTK; the disease is neoplasm.